J R Bogner1. 1. Sektion Klinische Infektiologie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Pettenkoferstr. 8a, 80336, München, Deutschland, jbogner@med.lmu.de.
Abstract
BACKGROUND: Therapeutic efficacy and safety in infections due to multiresistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase of multiresistant gram-negative and gram-positive organisms, new antibiotics are urgently needed. This paper provides a review of new pharmaceuticals which are already in clinical development, mainly in phase III trials. CONCLUSION: Each of these new trials increases the possibility of new antibiotics receiving approval.
BACKGROUND: Therapeutic efficacy and safety in infections due to multiresistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase of multiresistant gram-negative and gram-positive organisms, new antibiotics are urgently needed. This paper provides a review of new pharmaceuticals which are already in clinical development, mainly in phase III trials. CONCLUSION: Each of these new trials increases the possibility of new antibiotics receiving approval.
Authors: Gregory J Moran; Edward Fang; G Ralph Corey; Anita F Das; Carisa De Anda; Philippe Prokocimer Journal: Lancet Infect Dis Date: 2014-06-05 Impact factor: 25.071
Authors: S Flanagan; S L Minassian; D Morris; R Ponnuraj; T C Marbury; H W Alcorn; E Fang; P Prokocimer Journal: Antimicrob Agents Chemother Date: 2014-08-18 Impact factor: 5.191
Authors: Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2012-04-23 Impact factor: 5.191
Authors: Takehiko Mima; Brian H Kvitko; Drew A Rholl; Malcolm G P Page; Eric Desarbre; Herbert P Schweizer Journal: Int J Antimicrob Agents Date: 2011-05-18 Impact factor: 5.283
Authors: Helio S Sader; David J Farrell; Mariana Castanheira; Robert K Flamm; Ronald N Jones Journal: J Antimicrob Chemother Date: 2014-06-10 Impact factor: 5.790
Authors: Shawn Flanagan; Edward Fang; Kelly A Muñoz; Sonia L Minassian; Philippe G Prokocimer Journal: Pharmacotherapy Date: 2014-07-03 Impact factor: 4.705